190 related articles for article (PubMed ID: 7920220)
1. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
Witzig TE; Weitz JJ; Lundberg JH; Tefferi A
Leuk Lymphoma; 1994 Jun; 14(1-2):137-9. PubMed ID: 7920220
[TBL] [Abstract][Full Text] [Related]
2. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Juliusson G; Elmhorn-Rosenborg A; Liliemark J
N Engl J Med; 1992 Oct; 327(15):1056-61. PubMed ID: 1355853
[TBL] [Abstract][Full Text] [Related]
3. New purine analogues for the treatment of chronic B-cell malignancies.
Gribbin TE
Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
Zaja F; Di Loreto C; Amoroso V; Salmaso F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Mariuzzi L; Beltrami CA; Baccarani M
Leuk Lymphoma; 1998 Feb; 28(5-6):567-72. PubMed ID: 9613987
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592
[No Abstract] [Full Text] [Related]
6. Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
Jeong KH; Lew BL; Sim WY
Acta Derm Venereol; 2009; 89(5):509-12. PubMed ID: 19734979
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
8. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
Tefferi A; Phyliky RL
Mayo Clin Proc; 1992 May; 67(5):457-61. PubMed ID: 1405771
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
Kantarjian HM; Childs C; O'Brien S; Huh Y; Beran M; Schachner J; Koller C; Keating MJ
Am J Med; 1991 Feb; 90(2):223-8. PubMed ID: 1996592
[TBL] [Abstract][Full Text] [Related]
10. Purine analogues for treatment of refractory essential mixed cryoglobulinemia.
Enzenauer RJ; Judson PH
Mayo Clin Proc; 1997 Jan; 72(1):92-3. PubMed ID: 9005296
[No Abstract] [Full Text] [Related]
11. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
12. Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Adiga GU; Abebe L; Wiernik PH
Am J Hematol; 2003 Apr; 72(4):267-73. PubMed ID: 12666139
[TBL] [Abstract][Full Text] [Related]
13. The purine analogs--a therapeutic beauty contest.
Cheson BD
J Clin Oncol; 1992 May; 10(5):868-71. PubMed ID: 1349035
[No Abstract] [Full Text] [Related]
14. [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
Valiev TT; Vinogradova IuE; Chernova NG; Mar'in DS; Volkova IaK; Petrova VI; Bulanov AIu; Kalinin NN; Semenova EA; Gretsov EM; Kravchenko SK; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2006; 78(7):87-90. PubMed ID: 16944758
[No Abstract] [Full Text] [Related]
15. Chlorambucil and prednisolone therapy in a patient with T-cell chronic lymphocytic leukaemia.
Islam A; Majer R; Cumber P; Poynton C
Clin Lab Haematol; 1996 Jun; 18(2):125-6. PubMed ID: 8866149
[No Abstract] [Full Text] [Related]
16. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
[TBL] [Abstract][Full Text] [Related]
18. B-CLL in PLL transformation associated with hypercalcemia.
Lerner D; Esteves C; De Oliveira MS
Leuk Lymphoma; 1994 Jan; 12(3-4):321-5. PubMed ID: 8167564
[TBL] [Abstract][Full Text] [Related]
19. The purine analogs--a therapeutic beauty contest.
Cheson BD
J Clin Oncol; 1992 Mar; 10(3):352-5. PubMed ID: 1346799
[No Abstract] [Full Text] [Related]
20. Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Doorduijn JK; Michiels JJ
Leukemia; 1994 Aug; 8(8):1439. PubMed ID: 8057685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
